Nektar Therapeutics (NKTR) and Takeda Pharmaceutical (TKPYY) are collaborating to evaluate Nektar’s investigational medicine, NKTR-214, with Takeda’s investigational medicine, TAK-659, as a potential combination for multiple cancer settings.
NKTR-214 is an experimental immuno-stimulatory recognized to expand specific cancer-fighting T cells and natural killer (NK) cells directly into the cancer micro-environment. The drug also increases the expression of PD-1 on these immune cells.
TAK-659 inhibits both spleen tyrosine kinase (SYK), which is involved in . . .